Sareum Holdings, the specialist drug development company, noted yesterday that Sierra Oncology, Inc, the licence holder for SRA737 (a novel Chk1 inhibitor), had agreed to be acquired by GlaxoSmithKline for US$1.9bn in cash. The transaction is expected to close in the third quarter of 2022 or before. GSK has noted that the key driver of the acquisition was momelotinib, a drug Sierra is developing for the treatment of myelofibrosis, which reported positive topline results in a Phase III study in J ....
